Alexion
NEWS
Alexion Pharmaceuticals announced positive results from its pivotal Phase III clinical trial for a life-threatening blood disease.
Moriarty and Wagner will not be making the move to Boston and will be leaving the company at the end of this month.
With 2018 expected to be a big year for mergers and acquisitions in the biopharma industry, analysts and investors are considering who the top targets might be.
Although the stock market seems to be moving up at the beginning of this year, the U.S. equities market appears more mixed, with healthcare stocks in particular appearing more volatile.
The analyst identified Vertex and Alexion as his top two picks among large cap biotechs in 2018.
A new RBC report is reasonably positive on the biotech sector for 2018 and here are some reasons why.
We now turn to six MoneyShow.com contributors for their best ideas in biotechnology, a sector with both high risk and the potential for high rewards.
This year wasn’t big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016.
Despite a purge of the leadership team at Alexion, a key investor believes the company needs to do more in order to address its damaged reputation and lift its stock price.
JOBS
IN THE PRESS